ArticleClinical kidney journal2020

Erratum: The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

William G Herrington et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.